Effects of Semisupervised Exercise Training on Health Outcomes in People With Lung or Head and Neck Cancer: Protocol for a Randomized Controlled Trial.
ECOG
ENDT
Eastern Cooperative Oncology Group
HRQoL
QoL
RCT
aerobic exercise
cancer treatment
drug therapy
ear nose throat
ear, nose, and throat
exercise
head and neck neoplasms
head cancer
lung cancer
lung neoplasms
muscle strength
neck cancer
neoplasm
oncology
outpatient
physical activity
pulmonary
quality of life
radiotherapy
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
24 May 2023
24 May 2023
Historique:
received:
23
12
2022
accepted:
21
03
2023
revised:
21
03
2023
medline:
24
5
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
Lung or head and neck cancers are known for their high prevalence and mortality rates. Chemotherapy and radiotherapy are usually recommended as cancer treatment for these malignancies; however, they can negatively impact both the physical and mental status of patients. Hence, it is reasonable to consider resistance and aerobic exercise training to prevent these negative health outcomes. Further, several factors prevent patients from attending outpatient exercise training programs, and, therefore, a semisupervised home-based exercise training program may be seen as a well-accepted alternative. The aim of this study will be to investigate the effects of a semisupervised home-based exercise training program on physical performance, body composition, and self-reported outcomes; changes in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival in people with primary lung or head and neck cancer. Participants will be randomly allocated to the training group (TG) or control group (CG). The TG will undergo semisupervised home-based resistance and aerobic exercise training throughout their cancer treatment. The resistance training will be performed using elastic bands (TheraBand) twice a week. The aerobic training (ie, brisk walk) will be performed for at least 20 minutes per day outdoors. The equipment and tools used during the training sessions will be provided. This intervention will start the week before treatment commencement, will be performed throughout the duration of the treatment, and will continue for 2 weeks after treatment completion. The CG will undergo usual care (ie, cancer treatment with no formal exercise prescription). Assessments will take place 2 weeks before the beginning of the usual cancer treatment and 2 weeks after treatment completion. The measures of physical function (peripheral muscle strength, functional exercise capacity, and physical activity), body composition, and self-reported outcomes (symptoms of anxiety and depression, health-related quality of life, and symptoms related to the disease and treatment) will be collected. We will report on any change in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival. In February 2021, the clinical trial registration was approved. Recruitment and data collection for the trial are ongoing (as of April 2023, 20 participants had already been randomized), and findings of this study are likely to be published late in 2024. This exercise training as a complementary treatment for patients with cancer is likely to promote positive effects on the health outcomes assessed, over and above any change in the CG, and prevent the reduction of initial cancer treatment dose prescribed. If these positive effects are shown, they will likely impact long-term outcomes such as hospitalizations and 12-month survival. Brazilian Clinical Trials Registry (ReBEC) RBR-5cyvzh9; https://ensaiosclinicos.gov.br/rg/RBR-5cyvzh9. PRR1-10.2196/43547.
Sections du résumé
BACKGROUND
BACKGROUND
Lung or head and neck cancers are known for their high prevalence and mortality rates. Chemotherapy and radiotherapy are usually recommended as cancer treatment for these malignancies; however, they can negatively impact both the physical and mental status of patients. Hence, it is reasonable to consider resistance and aerobic exercise training to prevent these negative health outcomes. Further, several factors prevent patients from attending outpatient exercise training programs, and, therefore, a semisupervised home-based exercise training program may be seen as a well-accepted alternative.
OBJECTIVE
OBJECTIVE
The aim of this study will be to investigate the effects of a semisupervised home-based exercise training program on physical performance, body composition, and self-reported outcomes; changes in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival in people with primary lung or head and neck cancer.
METHODS
METHODS
Participants will be randomly allocated to the training group (TG) or control group (CG). The TG will undergo semisupervised home-based resistance and aerobic exercise training throughout their cancer treatment. The resistance training will be performed using elastic bands (TheraBand) twice a week. The aerobic training (ie, brisk walk) will be performed for at least 20 minutes per day outdoors. The equipment and tools used during the training sessions will be provided. This intervention will start the week before treatment commencement, will be performed throughout the duration of the treatment, and will continue for 2 weeks after treatment completion. The CG will undergo usual care (ie, cancer treatment with no formal exercise prescription). Assessments will take place 2 weeks before the beginning of the usual cancer treatment and 2 weeks after treatment completion. The measures of physical function (peripheral muscle strength, functional exercise capacity, and physical activity), body composition, and self-reported outcomes (symptoms of anxiety and depression, health-related quality of life, and symptoms related to the disease and treatment) will be collected. We will report on any change in the initial cancer treatment dose prescribed; number of hospitalizations at 3, 6, and 9 months; and 12-month survival.
RESULTS
RESULTS
In February 2021, the clinical trial registration was approved. Recruitment and data collection for the trial are ongoing (as of April 2023, 20 participants had already been randomized), and findings of this study are likely to be published late in 2024.
CONCLUSIONS
CONCLUSIONS
This exercise training as a complementary treatment for patients with cancer is likely to promote positive effects on the health outcomes assessed, over and above any change in the CG, and prevent the reduction of initial cancer treatment dose prescribed. If these positive effects are shown, they will likely impact long-term outcomes such as hospitalizations and 12-month survival.
TRIAL REGISTRATION
BACKGROUND
Brazilian Clinical Trials Registry (ReBEC) RBR-5cyvzh9; https://ensaiosclinicos.gov.br/rg/RBR-5cyvzh9.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
PRR1-10.2196/43547.
Identifiants
pubmed: 37223986
pii: v12i1e43547
doi: 10.2196/43547
pmc: PMC10248778
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e43547Informations de copyright
©Isis Grigoletto, Vinicius Cavalheri, Luis Alberto Gobbo, Karina Pozo, Enio Rodrigues Maia Filho, Diogo Gonçalves Ribeiro, Nara Ielo, Fabiano Francisco De Lima, Ercy Mara Cipulo Ramos. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 24.05.2023.
Références
Pulmonology. 2018 Nov - Dec;24(6):354-357
pubmed: 30554670
Curr Sports Med Rep. 2009 Jul-Aug;8(4):176-81
pubmed: 19584603
Eur J Cancer. 1994;30A(9):1326-36
pubmed: 7999421
BMC Cardiovasc Disord. 2011 Feb 01;11:7
pubmed: 21284837
Qual Life Res. 2007 Aug;16(6):1019-28
pubmed: 17479356
Cancer Nurs. 2012 Jan-Feb;35(1):48-54
pubmed: 21558852
Thorax. 2019 Aug;74(8):787-796
pubmed: 31048509
Acta Oncol. 2011 Feb;50(2):307-13
pubmed: 21231792
J Pain Symptom Manage. 2018 May;55(5):1364-1381.e5
pubmed: 29309818
Eur Respir J. 2014 Dec;44(6):1428-46
pubmed: 25359355
J Thorac Oncol. 2015 Jun;10(6):861-71
pubmed: 25831230
Med Sci Sports Exerc. 2014 Apr;46(4):656-63
pubmed: 24042307
Support Care Cancer. 2012 Aug;20(8):1709-17
pubmed: 21947412
J Pain Symptom Manage. 2013 May;45(5):811-21
pubmed: 23017624
Nature. 2019 Mar;567(7748):305-307
pubmed: 30894741
Clin Oncol (R Coll Radiol). 2010 Apr;22(3):208-21
pubmed: 20110159
Curr Oncol Rep. 2018 Mar 10;20(3):27
pubmed: 29525828
Clin Chem. 2008 Nov;54(11):1770-9
pubmed: 18801934
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Clin Rehabil. 2014 Nov;28(11):1096-106
pubmed: 24647863
Arch Phys Med Rehabil. 2018 Dec;99(12):2595-2620
pubmed: 29738745
Support Care Cancer. 2018 Apr;26(4):1289-1295
pubmed: 29090387
Head Neck. 2020 Jun;42(6):1218-1226
pubmed: 32343013
Curr Opin Support Palliat Care. 2017 Sep;11(3):247-257
pubmed: 28562375
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):664-672
pubmed: 29766660
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur Respir J. 2017 Mar 2;49(3):
pubmed: 28254766
Zhonghua Jie He He Hu Xi Za Zhi. 2007 Jan;30(1):27-30
pubmed: 17326969
J Physiother. 2016 Apr;62(2):60-7
pubmed: 26992323
Support Care Cancer. 2014 Jan;22(1):95-101
pubmed: 23995813
Braz J Phys Ther. 2013 Nov-Dec;17(6):556-63
pubmed: 24271092
BMC Cancer. 2012 Dec 05;12:572
pubmed: 23216897
J Clin Oncol. 2015 Jun 10;33(17):1918-27
pubmed: 25918291
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Support Care Cancer. 2017 Jun;25(6):1749-1758
pubmed: 28102437
Public Health Nutr. 2006 Sep;9(6):755-62
pubmed: 16925881
J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39
pubmed: 26285247
Scand J Med Sci Sports. 2012 Dec;22(6):804-15
pubmed: 21599754
Oncologist. 2007;12 Suppl 1:4-10
pubmed: 17573451
Med Sci Sports Exerc. 2007 Aug;39(8):1423-34
pubmed: 17762377
Braz J Phys Ther. 2017 Jan - Feb;21(1):58-68
pubmed: 28442076
Physiother Theory Pract. 2022 Jan;38(1):14-27
pubmed: 31975638